ReviewChest2020
Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic.
Review in Chest, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 79 citations in OpenAlex.
- A wearable eddy current based pulmonary function sensor for continuous non-contact point-of-care monitoring during the COVID-19 pandemic.Scientific reports · 2021Trial
- Remote Patient Monitoring for Managing Interstitial Lung Disease: A Mixed-Methods Process Evaluation.CHEST pulmonary · 2025Article
- The interstitial lung disease patient pathway: from referral to diagnosis.ERJ open research · 2025Article
- Clinical impact of idiopathic pulmonary fibrosis on SARS-CoV-2 patient outcomes: a comprehensive analysis in the pre-vaccination era.Frontiers in medicine · 2025Article
- Discovery of common molecular signatures and drug repurposing for COVID-19/Asthma comorbidity: ACE2 and multi-partite networks.Cell cycle (Georgetown, Tex.) · 2024Article
- Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment.Frontiers in medicine · 2024Review
- Idiopathic Pulmonary Fibrosis and Post-COVID-19 Lung Fibrosis: Links and Risks.Microorganisms · 2023Review
- A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease.Respiratory research · 2022Review
- Management of chronic respiratory diseases during viral pandemics: A concise review of guidance and recommendations.Journal of family medicine and primary care · 2022Review
- Challenges in the Management of Post-COVID-19 Pulmonary Fibrosis for the Latin American Population.Journal of personalized medicine · 2022Article
- Mortality and Its Predictors in COVID-19 Patients With Pre-existing Interstitial Lung Disease.Cureus · 2022Article
- Characteristics and outcomes of COVID-19 patients with IPF: A multi-center retrospective study.Respiratory medicine and research · 2022Review
- Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases.Archivos de bronconeumologia · 2022Review
- Survivorship Analysis in Asymptomatic COVID-19+ Hip Fracture Patients: Is There an Increase in Mortality?Hip & pelvis · 2022Article
- How COVID-19 interacts with interstitial lung disease.Breathe (Sheffield, England) · 2022Review
- Role of methyle blue in the management of mild, moderate and severe COVID-19 disease.Journal of family medicine and primary care · 2022Article
- Effect of chronic lung diseases on mortality of prevariant COVID-19 pneumonia patients.Frontiers in medicine · 2022Article
- Idiopathic pulmonary fibrosis telemedicine management during COVID-19 outbreak.Open medicine (Warsaw, Poland) · 2022Article
- Telehealth for patients with interstitial lung diseases (ILD): results of an international survey of clinicians.BMJ open respiratory research · 2021Article
- The opportunities and challenges of social media in interstitial lung disease: a viewpoint.Respiratory research · 2021Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, has affected virtually all aspects of patient care. Health-care systems around the world are trying simultaneously to treat patients with COVID-19, prepare for its long-term impacts, and treat patients with other acute and chronic diseases. There are multiple ways that the COVID-19 pandemic will directly affect patients with fibrotic interstitial lung disease (ILD), particularly given their common risk factors for poor outcomes. Major issues for patients with ILD will include restricted access to key components of the diagnostic process, new uncertainties in the use of common ILD pharmacotherapies, limited ability to monitor both disease severity and the presence of medication adverse effects, and significantly curtailed research activities. The purpose of this review is to summarize how COVID-19 has impacted key components of the diagnosis and management of fibrotic ILD as well as to provide strategies to mitigate these challenges. We further review major obstacles for researchers and identify priority areas for future ILD research related to COVID-19. Our goals are to provide practical considerations to support the care of patients with ILD during the COVID-19 pandemic and to provide a road map for clinicians caring for these patients during future infectious disease outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.